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individualized prognostic in-
formation. Demographic,
tumor, and treatment data
from 548 patients were used
to develop a model for pre-
dicting the survival of indi-
vidual patients. The model
was validated in 2 external
data sets. The results can be
used for survival prediction,
and the baseline model can
be further improved in the
future.Methods and Materials: Data from 548 patients with stage III NSCLC were available
to enable the development of a prediction model, using stratified Cox regression. Vari-
ables were selected by using a bootstrap procedure. Performance of the model was
expressed as the c statistic, assessed internally and on 2 external data sets (nZ174
and nZ130).
Results: The final multivariate model, stratified for treatment, consisted of age,
gender, World Health Organization performance status, overall treatment time, equiv-
alent radiation dose, number of positive lymph node stations, and gross tumor volume.
The bootstrapped c statistic was 0.62. The model could identify risk groups in external
data sets. Nomograms were constructed to predict an individual patient’s survival
probability (www.predictcancer.org). The data set can be downloaded at https://
www.cancerdata.org/10.1016/j.ijrobp.2015.02.048.
Conclusions: The prediction model for overall survival of patients with stage III
NSCLC highlights the importance of combining patient, clinical, and treatment vari-
ables. Nomograms were developed and validated. This tool could be used as a first
building block for a decision support system.  2015 The Authors. Published by Else-
vier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
In Europe, lung cancer is by far the most common cause of
cancer death in men and the third cause of cancer deaths in
women (1), and in the United States, lung cancer death
holds the first position for both sexes (2). In 2012, more
than 400,000 new cases were diagnosed in Europe.
Approximately 30% of patients with non-small cell lung
cancer (NSCLC) receive a diagnosis of stage III disease.
The heterogeneity in this patient group makes it difficult
to choose the optimal treatment for an individual patient (3).
Moreover, this heterogeneity is becomingmore prominent as
new imaging modalities, genomics, and proteomics ap-
proaches are being used to describe tumors and patients. In
addition, the number of treatment options is rising and in-
cludes individualized chemotherapy, targeted agents, new
radiation therapy schemes and techniques, proton therapy,
surgery, or a combination of these options. A decision sup-
port system (DSS) could offer assistance for treatment de-
cision making but is currently lacking. This system should
incorporate multiple models to predict several relevant out-
comes for different treatment options (4) (Fig. E1, available
online atwww.redjournal.org). Amodel that consists of basic
clinical variables and predicts survival outcome for individ-
ual patients could serve as a first building block for this DSS.
In addition, more accurate prediction of survival would allow
identification of patients with comparable prognoses and
could be useful for risk stratification in clinical trials. Also,
doctors and patients would have better information about the
prognosis and could take this into account in a shared deci-
sion making process.
During recent decades, numerous studies have investi-
gated prognostic and predictive factors for lung cancer
survival. By contrast, studies especially focusing on stage
III NSCLC are relatively scarce (5).The aim of this study was to develop and validate a
prediction model for survival of stage III NSCLC patients,
treated with (chemo) radiation therapy, taking into account
all available and established prognostic factors.Methods and Materials
Patient population
Between March 2002 and August 2011, data were collected
prospectively for several patient cohorts (NCT00181545
clinicaltrials.gov, NCT00181506 clinicaltrials.gov, NCT00
572325 clinicaltrials.gov, NCT00573040 clinicaltrials.gov,
NCT01166204 clinicaltrials.gov, NCT01084785 clinical
trials.gov, NCT01936571 clinicaltrials.gov), ensuring
standardization and high quality of data. All patients were
treated with radiation therapy with curative intent at the
MAASTRO Clinic. For the current analysis, all inoperable
patientswith stage IIINSCLC (according to the 6th edition of
the TNM staging system) were selected. Patients were
excluded from the study if (1) they had received a diagnosis
of another primary tumor less than 5 years ago; (2) positron
emission tomography (PET)was not used for staging; and (3)
they had malignant pleural effusion. In addition, 2 patients
were lost to follow-up, 2 patients refused treatment, and 4
patients died during the course of radiation therapy. The
statistical analysis is based on 548 patients. The primary
gross tumor volume (GTVprimary) and the nodal gross tumor
volume (GTVnodal) were delineated manually, using infor-
mation from PET and computed tomography (CT). For pa-
tients treated with sequential chemotherapy, these volumes
were calculated using postchemotherapy imaging informa-
tion. The number of positive lymph node stations was
assessed by the nuclear medicine specialist using either an
Volume 92  Number 4  2015 Predicting survival for stage III NSCLC 937integrated 18F-fluorodeoxyglucose (FDG)-PET-CT scan or a
CT scan combined with FDG-PET scan. T stage and N stage
were assessed using pretreatment CT, PET, and mediastino-
scopy when applicable. For patients treated with sequential
chemotherapy, stage and the number of positive lymph node
stations were assessed using prechemotherapy imaging
information.
Radiation therapy development cohort
All patients were treated at the MAASTRO Clinic, using
CT-based radiation therapy planning. No elective nodal
irradiation was performed, and irradiation was delivered
5 days per week. Patients were treated with 3-dimensional
conventional radiation therapy (3D-CRT) (2002 to January
2010) or intensity modulated radiation therapy (IMRT)
(February 2010 to 2011).
Four different radiation treatment regimens were
applied.
1. Twenty-five patients were included in a phase 1 dose
escalation study (6). They received a total radiation dose
ranging from 61.2 to 68.4 Gy, delivered twice daily in
fractions of 1.8 Gy.
2. The second group consisted of 135 patients who were
treated according to the standard protocol, used until
August 2005. They received 60 Gy in daily fractions of
2 Gy.
3. One hundred eighty-seven patients were treated accord-
ing to the standard protocol that was introduced in
August 2005 (7). The radiation dose ranged from 54.0 to
79.2 Gy, delivered in fractions of 1.8 Gy twice daily,
depending on the mean lung dose or the spinal cord dose
constraint.
4. Since August 2008, concurrent chemoradiation was
delivered to patients judged to be physically fit to un-
dergo this treatment (8). A total of 201 patients received
a total dose of 45 Gy, delivered in 1.5 Gy-fractions twice
daily. Subsequently, a dose ranging from 4.0 to 24.0 Gy
was delivered in 2.0 Gy fractions once daily, depending
on the mean lung dose and the spinal cord dose
constraint.
The equivalent dose in 2-Gy fractions (EQD2) was used
as a measure for the intensity of chest radiation therapy
delivered to the tumor (9). Adjustment for dose per fraction
was made as follows:
EQD2ZD 
0
B@dþ
a
b
2þ ab
1
CA
where DZ the total radiation dose, dZ dose per fraction,
a/b Z 10 Gy.Chemotherapy
Two hundred eighty-two patients, treated according to
regimens 1 through 3, received chemotherapy before radi-
ation therapy started (Table 1). The regimen consisted of
carboplatin on day 1 and gemcitabine on days 1 and 8. The
majority received 3 cycles (range, 1-6). Patients treated
according to regimen 4 received concurrent chemo-
radiation, which consisted of 1 to 2 cycles of carboplatin
and gemcitabine, followed by concurrent cisplatin-
vinorelbine or concurrent cisplatin-etoposide every 3 weeks
with radiation therapy. The regimen depended on the
referring hospital. Dose reduction was applied according to
guidelines and in case of renal failure cisplatin was
substituted by carboplatin.
Survival endpoint
Overall survival was defined as the duration between the
start of radiation therapy and the date of death. Survival
status for the development cohort was evaluated in
December 2013 using a population registration system.
Data were considered right-censored if patients were alive
at the time point of evaluation.
Statistical analysis
The Kaplan-Meier method was used for univariate survival
analysis. To build a multivariate prediction model, Cox
regression was applied. It was assumed that the treatment
choice partially depended on the characteristics of the
patient cohorts. To correct for this so-called “confounding
by indication,” the analysis was stratified by treatment
cohort: (1) radiation therapy only; (2) treated with
sequential chemoradiation according to standard protocol;
(3) treated with concomitant chemoradiation according to
standard protocol; and (4) sequential chemoradiation for
patients who were not eligible for concomitant chemo-
radiation (Fig. E2, available online at www.redjournal.org).
Continuous variables were modeled nonlinearly by
applying restricted cubic splines (10, 11). If possible, the
nonlinear terms were replaced by simpler transformations
afterward. Variable selection was performed with a boot-
strap procedure. First, it was determined how many vari-
ables should be included in the model by performing
backwards variable selection for 100 bootstrap samples.
Subsequently, backwards selection on the original data set
was applied to identify which variables should be retained
in the model. The final model was compared with 2 models
that included variables based on the TNM staging system.
The performance of the models was assessed in terms of
model fit and discrimination. Discrimination (ie ability to
classify patients correctly) was assessed using the c sta-
tistic. Its interpretation is comparable to the AUC: the
maximum value is 1.0 and indicates a perfect prediction
model, and a value of 0.5 indicates that patients are
Table 1 Patient characteristics
Variable
Development cohort Validation cohorts
MAASTRO Clinic (nZ548) NKI (nZ174) P* MSKCC (nZ130) P*
Mean age (y) 66 (SD 10) 63 (SD 10) <.001 67 (SD 11) .510
Gender .144 <.001
Male 379 (69.2%) 110 (63.2%) 63 (48.5%)
Female 169 (30.8%) 64 (36.8%) 67 (51.5%)
WHO-PS <.001 .013
0 192 (35.0%) - 48 (36.9%)
1 287 (52.4%) 139 (79.9%) 78 (60.0%)
2 63 (11.6%) 35 (20.1%) 4 (3.1%)
Missing 6 (1.0%) - -
Mean FEV1 (%) 76 (range 21-139) 78 (range 37 - 133) .292
Missing 71 (13.0%) 34 (19.5%)
BMI 24.9 (SD 4.3) NA - NA
Missing 179 (32.7%)
Nicotine use NA - <.001
No/former smoker 304 (55.5%) 100 (76.9%)
Current smoker 202 (36.9%) 30 (23.1%)
Missing 42 (7.7%) -
Clinical T stage .053 <.001
T1 74 (13.5%) 28 (16.1%) 27 (20.8%)
T2 172 (31.4%) 67 (38.5%) 42 (32.3%)
T3 60 (10.9%) 27 (15.5%) 27 (20.8%)
T4 216 (39.4%) 52 (29.9%) 31 (23.8%)
Missing 26 (4.7%) - 3 (2.3%)
Clinical N stage <.001
N0 95 (17.3%) 13 (7.5%)
N1 15 (2.7%) 7 (4.0%)
N2 267 (48.7%) 123 (70.7%)
N3 167 (30.5%) 31 (17.8%)
Missing 4 (0.7%)
Clinical overall stage <.001 NA
IIIA 199 (36.3%) 115 (66.1%)
IIIB 349 (66.1%) 58 (33.3%)
Missing 1 (0.6%)
Histology <.001
Adenocarcinoma 81 (14.8%) 35 (20.1%)
SCC 164 (29.9%) 54 (31.0%)
Large cell carcinoma 190 (34.7%) 78 (44.8%)
Other 93 (17.0%) 7 (4.0%)
Unknown 20 (3.7%) -
Median GTV (mL) (range) 51 (0-725) 99 (0-1822) <.001y 54 (0.3-1057) .360y
Missing 41 (7.5%) 5 (2.9%) -
PLNS .603 <.001
0 104 (19.0%) 36 (20.7%) 6 (4.6%)
1 107 (19.5%) 36 (20.7%) 14 (10.8%)
2 113 (20.6%) 32 (18.4%) 39 (30.0%)
3 69 (12.6%) 31 (17.8%) 36 (27.7%)
4 125 (22.9%) 39 (22.4%) 35 (26.9%)
Missing 30 (5.5%) -
Chemotherapy - .009
No 66 (12.0%) - 12 (9.2%)
Sequential 280 (51.1%) - 51 (39.2%)
Concurrent 202 (36.9%) 174 (100%) 67 (51.5%)
Mean OTT (d) 32 (SD 8) 31 (SD 2) .763 43 (SD 8) <.001
Mean EQD2 (Gray) 60.8 (SD 7.1) 70.1 (SD 0) - 60.1 (SD 8.8) .313
Abbreviations: BMI Z body mass index; EQD2 Z equivalent radiation dose at 2 Gy; FEV1 Z forced expiratory volume in 1 second; GTV Z gross
tumor volume; MSKCC Z Memorial Sloan Kettering Cancer Center; NKI Z Netherlands Cancer Institute; OTT Z overall treatment time radiation
therapy; PLNS Z number of positive lymph node stations; SCC Z squamous cell carcinoma; SD Z standard deviation; WHO-PS Z World Health
Organization performance status.
* P values assessed using t test (continuous variables) or c2 test (categorical variables).
y P values assessed using Mann-Whitney test (nonparametric distribution).
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chance). To correct for a too optimistic estimation of the c
statistic, bootstrapping was applied (11). Akaike’s infor-
mation criterion (AIC) is a trade-off between model fit and
number of included variables and can be used to compare
nonnested models. The preferred model is the one with the
lowest AIC value. The difference can be interpreted as
follows: a decrease by 4 to 7 indicates weak support; a
decrease by 10 indicates strong support for a model. Dif-
ferences of 0 to 3 indicate that performance is comparable
(12, 13). To assess the model performance on the external
data sets, the cohort was split into 3 subgroups, based on
25th and 75th percentile of the risk score (14). For these
subgroups a calibration plot, in which the predicted prob-
ability is compared with the observed outcome, and
Kaplan-Meier curves were made. Nomograms were made
for practical use. The analysis was performed with SPSS,
version 19.0 (SPSS Inc, Chicago, IL) and R, version
2.14.0, using the RMS library (Harrell).
External validation cohorts
The validation cohorts consisted of 174 and 130 patients
with stage III NSCLC treated with sequential or concurrent
chemoradiation, or radiation therapy alone, at the
Netherlands Cancer Institute (NKI) and Memorial Sloan
Kettering Cancer Center (MSKCC), respectively. Staging
was performed using FDG-PET information. All NKI pa-
tients received definitive concurrent chemoradiation with
IMRT (Table 1) (15). No elective irradiation was per-
formed. Treatment consisted of 24 fractions of 2.75 Gy and
daily cisplatin. The MSKCC cohort was treated with con-
ventional 3D radiation therapy or IMRT, and chemotherapy
consisted of a cisplatin doublet or, less commonly, carbo/
taxol every 3 weeks (16, 17).
Ethics
This study was conducted according to national laws and
guidelines and approved by the local review boards.
Results
Development cohort
Table 1 depicts the characteristics of the development
cohort and the validation cohort. Of all patients, 456
(83.2%) had died at the time of the analysis. The median
follow-up time was 5.5 years (range, 1.3-10.0 years). The
median survival for the whole group was 16 months (95%
confidence interval [CI]: 14-19 months), with a 2-year
survival of 39% (95% CI: 32%-46%) for stage IIIA dis-
ease and 36% (95% CI: 31%-41%) for stage IIIB disease
(log-rank PZ.84). The associations between EQD2 and
OTT or GTV are shown in Figure E8 (available online at
www.redjournal.org).External validation cohort
There were several statistically significant differences be-
tween the MAASTRO Clinic cohort and the validation
cohorts (Table 1). The mean GTV of patients treated at the
NKI was larger, and the radiation therapy dose was
significantly higher. In addition, the NKI cohort was more
homogeneous with respect to World Health Organization
(WHO) performance status, chemotherapy, OTT, and
EQD2. The median follow-up time was 28 months (range,
2-49 months). The 2-year overall survival was 51% (95%
CI: 43%-59%). The MSKCC cohort consisted of a higher
percentage of women, fewer smokers, and fewer T4 tumors.
There were only a few patients with N0. Compared with the
MAASTRO Clinic cohort, more patients received concur-
rent chemoradiation, and the OTT was longer. The median
follow-up time was 62 months (range, 6-97 months). The 2-
year overall survival was 44% (95% CI: 36%-54%).Multivariate model
The variables available for model building were treatment
cohort (stratification factor), age, gender, WHO perfor-
mance status, body mass index, forced expiratory volume
(in 1 second), clinical overall stage, T stage, N stage,
number of positive lymph node stations (PLNS), GTV,
OTT, and EQD2. After the variable selection procedure, the
final model consisted of gender, WHO performance status,
T stage, GTV, PLNS, OTT, and EQD2 (Table 2). Age was
included in the model although it was statistically not
significant. The association of GTV, OTT, and age with
survival was modeled nonlinearly. The hazard of death did
not further increase for GTVs larger than approximately
150 mL, nor did the hazard further decrease for treatment
times shorter than approximately 28 days or age <70
(Fig. E3, available online at www.redjournal.org). These
nonlinear relationships could be approximated very well by
a log transformation for GTV and a piecewise linear
function, consisting of 2 straight-line sections, for OTT and
age (Fig. 1). These simplifications did not result in a
decreased performance. The c statistic of the final model
was 0.65 (0.62 after correction for optimism). Comparison
with 2 models that included variables based on the TNM
staging system showed that model fit and predictive per-
formance were better for the multivariate model (Table 3).
Application of the model on the data sets of the NKI and
MSKCC resulted in c statistics of 0.58 and 0.60, respec-
tively. Although the differences between observed and
predicted survival probabilities were small for the NKI
cohort, there were considerable disparities for the MSKCC
cohort (Fig. E4, available online at www.redjournal.org).
The model underestimated overall survival for the MSKCC
patients. To create Kaplan-Meier curves, the validation
cohorts were split into 3 subgroups based on the 25th and
75th percentile of the predicted probability (14). For the
NKI cohort, a high-risk group could be identified, but the
Table 2 Hazard ratios for overall survival*
Variable Values Coef SE HR 95% CI P
Sex Male ref .011
Female 0.28 0.11 0.76 0.61-0.94
Age (y) 70 ref
0.024 0.015 1.02 0.99-1.05 .1402
WHO-PS 0 ref .0008
1 0.31 0.11 1.37 1.11-1.68
2 0.52 0.16 1.68 1.22-2.31
PLNS 0 ref <.0001
1 0.27 0.16 1.31 0.95-1.80
2 0.49 0.16 1.63 1.19-2.24
3 0.67 0.18 1.96 1.38-2.79
4 0.79 0.18 2.21 1.55-3.14
T stage T0/T1 ref .3135
T2 0.10 0,16 1,11 0.81-1.52
T3 0.32 0,21 1.8 0.92-2.07
T4 0.06 0.17 1.06 0.76-1.50
LN GTV (mL) 0.15 0.01 1.16 1.14-1.18 .0008
OTT (days) 28 ref
0.040 0.009 1.04 1.02-1.06 <.0001
EQD2 0.015 0.008 0.99 0.97-1.00 .0506
Abbreviations: CIZ confidence interval; CoefZ regression coefficient; EQD2Z equivalent radiation dose at 2 Gy; GTVZ gross tumor volume; LN
Z natural logarithm; OTTZ overall treatment time radiation therapy; PLNSZ number of positive lymph node stations; SEZ standard error; WHO-PS
Z World Health Organization performance status.
* Model is stratified by treatment.
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PZ.0006) (Fig. 2A), and identification of a low-risk group
was possible for the MSKCC cohort (log-rank PZ.059)
(Fig. 2B). Nomograms were developed for prediction of
24 months (Fig. 3) and 36 months overall survival (Fig. E5,
available online at www.redjournal.org). The model will
be freely available on www.predictcancer.org. In addition
to the point estimate, 95% confidence intervals are calcu-
lated on the website. The data set is publicly available on
https://www.cancerdata.org/10.1016/j.ijrobp.2015.02.048.Discussion
To our knowledge, this is the first prediction model for
overall survival of patients with stage III NSCLC treated
with (chemo) radiation therapy. The performance of the
model in the development cohort and in the validation data
sets was moderate, but evidently better than the perfor-
mance of the TNM-based models. We showed that accurate
risk stratification for these patients should be based on
multiple factors, including WHO performance status,
gender, PLNS, GTV, clinical T stage, chemotherapy, OTT,
and EQD2.
In agreement with the literature, where performance
status, regardless of resectability of the tumor, is con-
sistently identified as an important predictor for survival
(18, 19), we found that worse performance status was
associated with shorter survival.
Although some studies found no influence of gender
(20), there are also indications that female gender is afavorable factor for survival (21, 22). In our study, female
gender was prognostic for better survival.
Several prospective studies have suggested that higher
radiation doses lead to improved local control and higher
survival rates (7, 8, 23). However, the randomized RTOG
0617 trial, comparing 60 Gy with 74 Gy, showed a signifi-
cantly lower survival in the high-dose arm (24). This unex-
pected finding could be explained by any of several factors,
including the prolonged OTT and increased heart toxicity in
the high-dose group (25). Previously published studies have
reported a decrease in tumor control probability of 1.6% per
day after a 6-week duration of radiation therapy (26) and a
2.0% increase in the risk of death for each day of prolonga-
tion in therapy (27). This is due to accelerated repopulation,
which occurs if OTT is longer than approximately 35 to
42 days. In our study, patients were treated with a wide range
of doses and accelerated repopulation was avoided by
restricting the OTT to a maximum of approximately 40 days
(7, 8). Obviously, this heterogeneity made it possible to find
and model the dose-response relationship. The difference in
2-year survival (44% vs 51%) between the patients treated
with concurrent chemotherapy from the MAASTRO Clinic
cohort and those from the NKI cohort could possibly be
explained by the radiation dose scheme (9 Gy lower in the
MAASTRO Clinic cohort), indicating a beneficial effect of
dose intensification for these patients. Previously published
studies have reported a slightly increased survival for inter-
mediately escalated dose (28, 29). The survival difference
betweenMAASTROClinic andMSKCCmight be attributed
to a higher percentage of women and a lower percentage of
smokers. Also, differences in (introduction of) diagnostic
Fig. 1. Predictors in the final multivariable model, using transformed variables to simplify the model. No regression
coefficients are estimated for the treatment cohorts as overall survival is estimated by the Kaplan-Meier method for the strata
(treatment cohorts). EQD2Z equivalent dose in 2-Gy fractions; GTVZ gross tumor volume; OTTZ overall treatment time;
WHO-PS Z World Health Organization performance status.
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detection of brain metastases, or chemotherapy regimens for
both primary and second-line treatment, could have influ-
enced the case mix and thus explain our results. The fact that
the accuracy of themodel was higher for theNKI cohort from
the Netherlands than for the MSKCC cohort from the UnitedTable 3 Comparison of performance and model fit
Model Performance* 95% CI Py AIC
MV model with rcs 0.62 0.61-0.66 3945
Simplified MV model 0.62 0.61-0.66 3945
Stage IIIA vs
stage IIIB
0.54 0.52-0.58 <.001 4001
T stage þ N stage 0.57 0.56-0.61 <.001 3991
Abbreviations: AIC Z Aikaike’s information criterion; CI Z confi-
dence interval; MV Z multivariable; rcs Z restricted cubic splines.
* Performance assessed by bootstrap procedure.
y Comparison between simplified MV model and models based on
TNM stage.States indicates that these patient populations are not
completely comparable, but more research is needed to shed
light on the possible explanations (Fig. E4, available online at
www.redjournal.org).
Several groups have concluded that GTV is a highly sig-
nificant factor for the prediction of survival (30, 31). The
nonlinear relationship has been reported previously by the
MAASTROClinic (32) but alsobyothers (30, 33). In addition,
Ball et al (33) reported a time-dependent hazard ratio for the
GTV, but this finding was not replicated in our data (32). The
GTVwas themost important prognostic factor in our analysis.
The importance of a short OTT for survival outcome has
been reported in several studies (27, 34, 35). From a
radiobiological point of view it can be assumed that treat-
ment times shorter than 28 days do not further improve the
survival of NSCLC patients (9). Our clinical data support
this assumption.
Previously it has already been shown that PLNS
on FDG-PET scan is an important risk factor for
Fig. 2. Kaplan-Meier curves for overall survival of risk groups, based on the predicted probability for the external vali-
dation cohorts from (A) Y (nZ174) and (B) Z (nZ130). RT Z radiation therapy.
Oberije et al. International Journal of Radiation Oncology  Biology  Physics942non-surgically treated patients (32, 36). The current study
confirms these results. Although a recently updated meta-
analysis suggests that high standardized uptake value
(SUV) measured by FDG-PET is a poor prognostic factor
for survival in NSCLC patients, its role is less clear for
stage III patients (5). In addition, comparison of SUVsFig. 3. Nomogram for prediction of 24-month overall survival
can be obtained from the website www.predictcancer.org. Instruc
Draw a line straight upward to the points axis to determine how
for the other axes, each time drawing straight upward to the po
locate this sum on the “Total points” axis. Draw a line straigh
EQD2Z equivalent dose in 2-Gy fractions; GTVZ gross tumo
Z World Health Organization performance status.across institutes and countries is difficult because of the
lack of standardization. Therefore, using PLNS assessed by
FDG-PET instead of SUV-based measures enhances the
applicability of our model.
It can be concluded that the performance of our model, c
statistic of 0.62, is moderate, but evidently better than the. The outcome is a point estimate; 95% confidence intervals
tions for physician: Locate the patient’s age on the age axis.
many points a patients receives for age. Repeat this process
ints axis. Sum the points achieved for each predictor, and
t down to assess the survival probability for this patient.
r volume; PETZ positron emission tomography; WHO-PS
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overall stage or T stage and N stage (c statistic 0.50 and
0.55, respectively). The performance of these models
increased if treatment cohort was entered as a stratification
factor (0.54 and 0.57, respectively).
Given that our model was based on patients treated with
3D-CRT or IMRT, predictions for patients treated with
other techniques or treatment schemes should be inter-
preted carefully (for an example, See Text E7, available
online at www.redjournal.org). Moreover, the majority of
patients were treated according to a nonstandard dose
escalation protocol, which severely limits the applicability
of the nomogram. Therefore, the nomogram should not be
used to adapt treatment of individual patients. In addition,
only a point estimate is provided to indicate the predicted
probability, which can be misleading. It is possible to
obtain 95% confidence intervals from the website (www.
predictcancer.org).
The cutoff points to define the risk groups were pre-
defined to avoid over optimistic results. However, clinically
more relevant cutoff points could be chosen to select
patients for clinical trials or for specific treatment modal-
ities such as proton therapy (Fig. E1, available online at
www.redjournal.org).
Although predictive factors define the effect of treatment
on the outcome, prognostic factors indicate the effects of
patient or tumor characteristics. Inasmuch as our model
contains treatment characteristics that can be adapted, we
decided to use the term “prediction model,” although some
might opt for the term “prognostic.”
We validated our model in 2 external data sets, resulting
in c statistics of 0.59 and 0.60. The decrease was thus
limited and can probably be attributed to differences in case
mix. Moreover, the Kaplan-Meier curves show that it was
possible to identify risk groups in the validation cohorts
(Fig. 2).
The treatment of the patient cohort included in this study
was very heterogeneous, and the choice of treatment
regimen was partially guided by patients’ general health
and physical fitness, leading to “confounding by indica-
tion.” To adjust the survival curve for factors that cannot be
captured in the prognostic variables, a stratified analysis
was performed. We were able, despite the heterogeneity of
the population, to find several statistically significant and
clinically relevant patient and treatment characteristics that
were present in all strata.
Other factors with additional prognostic value could
further improve the model. Although some biomarkers
prognostic for survival have already been identified, these
results still have to be confirmed and validated on a larger
scale. In addition, genomics and proteomics analysis hold
great promise but still have their limitations in clinical
application (5, 37). Finally, radiomics, sophisticated anal-
ysis of imaging information, might provide new prognostic
or predictive factors (38, 39).
Although most studies focus on a specific group of
variables (eg biomarkers, genes, imaging, or clinicalcharacteristics) in our opinion integration of information
from multiple sources is the way forward toward more
accurate prediction models. For that purpose, large data-
bases, new modeling methods, and a culture of data sharing
are needed because it will be impossible to collect all this
information from the same group of patients or within 1
trial (40, 41).
The current model can be considered a first building block
of a DSS (4). Ultimately, this DSS should be tested pro-
spectively in a clinical trial. In our opinion, it is only a matter
of time until DSSs are introduced into clinical practice to
offer assistance for treatment decisionmaking by quantifying
the risks and the benefits of a specific treatment.
Although new factors are needed to improve the pre-
dictive capability of the survival model, and patient cohorts
treated with standard radiation dose should be included to
increase the applicability, our results are encouraging.
It is concluded that in this study, we developed and
validated a survival model for patients with stage III
NSCLC treated with (chemo) radiation. The model, which
estimates 2-year and 3-year survival of individual patients,
outperforms TNM-based models and could therefore pro-
vide clinicians and patients with more specific prognostic
information.
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